a20 cell line (ATCC)
Structured Review
A20 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1390 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a20+cell+line/A20/10__1038_slash_s41467___026___79209___x-376-1-8
Average 97 stars, based on 1390 article reviews
Images
Related Articles
Activity Assay:Article Title: Antibodies and nucleotide sequences, and uses thereof Article Snippet: .. Antitumoral Activity of VVTK RR-Encoding Anti-CTLA-4 and GM-CSF in Mice Bearing A20 Subcutaneous Murine B-Cell Lymphoma The Mouse Assay:Article Title: Antibodies and nucleotide sequences, and uses thereof Article Snippet: .. Antitumoral Activity of VVTK RR-Encoding Anti-CTLA-4 and GM-CSF in Mice Bearing A20 Subcutaneous Murine B-Cell Lymphoma The Derivative Assay:Article Title: Antibodies and nucleotide sequences, and uses thereof Article Snippet: .. Antitumoral Activity of VVTK RR-Encoding Anti-CTLA-4 and GM-CSF in Mice Bearing A20 Subcutaneous Murine B-Cell Lymphoma The Article Title: ISCOM-type matrix from beta-escin and glycyrrhizin saponins Article Snippet: .. Article Title: 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling pathways Article Snippet: .. Article Title: ISCOM-type matrix from beta-escin and glycyrrhizin saponins Article Snippet: .. Cell Culture:Article Title: Large-scale acoustic single cell trapping and selective releasing Article Snippet: Penicillin–streptomycin (PS) was purchased from Thermo Fisher Scientific (West Hills, CA). .. The other:Article Title: Combination of small molecule CD-47 inhibitors with other anti-cancer agents Article Snippet: When the mean tumor volumes reached approximately 75 mm3, the animals were randomized based on tumor volumes into four groups (G1 to G4) of twelve animals (N=12) each and dosed with vehicle, Compound 6, anti-mouse PD-L1 antibody and the combination of Compound 6 and anti-mouse PD-L1 antibody as mentioned below: Dose Group Compound Dose Frequency Route volume G1 Vehicle control 0 mg/kg Twice daily (bid) Oral 10 mL/kg G2 Compound 6 30 mg/kg Twice daily (bid) Oral 10 mL/kg G3 Anti-mouse PD- 200 μg/animal On Day 1, Day 3, i.p 100 μL/mouse L1 antibody Day 6 and Day 9 (Clone 10F.9G2) G4 Compound 6 + 30 mg/kg + Twice daily (bid) + Oral, 10 mL/kg, Anti-mouse PD- 200 μg/animal On Day 1, Day 3, i.p 100 μL/mouse L1 antibody Day 6 and Day 9 (Clone 10F.9G2) The treatment was continued for a period of 21 days, during which the overall efficacy and tolerability were evaluated based on tumor volume and body weight changes observed during the treatment period. |
